Find Funding Opportunities

Returning 185 results

Limited Competition: NeuroImaging Tools and Resources Collaboratory (R24 Clinical Trial Not Allowed)

RFA
Tuesday, December 18, 2018
Saturday, February 23, 2019
R24
RFA-EB-18-004

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Not Allowed)

RFA
Monday, December 17, 2018
Wednesday, March 20, 2019
U01
RFA-OD-19-014

Funding Opportunity Purpose

The National Institutes of Health (NIH) intends to publish a Funding Opportunity Announcement (FOA) to establish 5 new awards for the Research Evaluation and Commercialization Hubs (REACH) program to address the problems that hinder the critical, early steps necessary to translate novel scientific advances and discoveries into commercially viable diagnostics, devices, therapeutics, and tools that improve patient care and advance public health. The five awardees will participate in a technology development consortium that incorporates best practices from current pilot programs and fulfills the objectives of the Phase 0 Proof of Concept Partnership pilot program, in accordance with Section 5127 of the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81) and reauthorized through FY 2022 within H.R. 5515 Sec 854. The REACH program advances FY2020 Administration Research and Development Budget Priorities, including educating and training a workforce for the 21st century economy, transferring technology from the laboratory to the marketplace, and partnering with industry and academia to advance the RandD enterprise.

Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

PAR
Tuesday, December 11, 2018
Thursday, November 5, 2020
K43
PAR-19-098

Funding Opportunity Purpose

This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Data Integration, Algorithm Development and Operations Management Center (U24 Clinical Trial Not Allowed)

RFA
Monday, December 10, 2018
Thursday, March 21, 2019
U24
RFA-AR-19-027

Funding Opportunity Purpose

NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved understanding of the biological underpinnings of chronic pain and discovery and testing of new non-addictive pain treatments.

HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional)

RFA
Monday, December 10, 2018
Thursday, March 21, 2019
UH2/UH3
RFA-AR-19-028

Funding Opportunity Purpose

NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved understanding of the biological underpinnings of chronic pain and discovery and testing of new non-addictive pain treatments.

HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Mechanistic Research Centers (U19 Clinical Trial Optional)

RFA
Monday, December 10, 2018
Thursday, March 21, 2019
U19
RFA-AR-19-026

Funding Opportunity Purpose

NIAMS intends to publish a Funding Opportunity Announcement focused on acute and chronic back pain research using novel, inter and multidisciplinary integrated approaches and novel analytics for discovery of disease mechanisms and features for deep patient phenotyping and identification of new targets for intervention.

HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3 Clinical Trial Required)

RFA
Monday, December 10, 2018
Wednesday, February 27, 2019
UG3/UH3
RFA-AR-19-029

Funding Opportunity Purpose

NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved

HEAL Initiative: Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical Trial Not Allowed)

RFA
Monday, December 10, 2018
Friday, March 1, 2019
UH2/UH3
RFA-TR-19-005

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative

HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)

RFA
Monday, December 10, 2018
Tuesday, February 23, 2021
UH3
RFA-NS-19-018

Funding Opportunity Purpose

HEAL Initiative: This is a HEAL Initiative UH3 FOA that will solicit device applications to treat pain.

HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed)

RFA
Monday, December 10, 2018
Translational Research
Thursday, March 7, 2019
U44
RFA-NS-19-020

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Pages